Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03244280 · ClinicalTrials.gov registry record · Phase 1
A Study of the Systemic Absorption of MOB015B
A Phase 1 study, sponsored by Moberg Pharma AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03244280: Completed Phase 1 study, sponsored by Moberg Pharma AB.
NCT03244280 is a Phase 1 study that has completed, run by Moberg Pharma AB. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03244280, a Phase 1 study, has completed, sponsored by Moberg Pharma AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.
Primary Outcome
To measure the Cmax after 1 day and 28 days
Interventions
- DRUG MOB015B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-16 |
| Est. Completion | 2018-04-23 |
| Phase | Phase 1 |
What the finished NCT03244280 record still lists
NCT03244280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which MOB015B is the first listed.
NCT03244280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03244280 about?
NCT03244280 is a clinical study titled "A Study of the Systemic Absorption of MOB015B". A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.
What is the current status of trial NCT03244280?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-16. Estimated completion is 2018-04-23.
What interventions are being tested in trial NCT03244280?
The interventions under investigation include: MOB015B (DRUG).
Who is sponsoring clinical trial NCT03244280?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03244280's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI